Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Omega-6 oil may boost insulin sensitivity in At-Risk adults

NCT ID NCT07287514

Disease control Sponsor: Pontificia Universidad Catolica de Chile Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether taking a daily oil rich in linoleic acid (a type of omega-6 fat) for 8 weeks can improve insulin resistance in adults aged 20-60 who have this condition plus at least one other cardiometabolic risk factor (like abdominal obesity or high blood pressure). Participants will be randomly assigned to receive either the linoleic acid oil or a control blended oil, while keeping their usual diet. The main goal is to see if the oil reduces insulin resistance, which could help manage metabolic disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men and women aged 20 to 60 years. * Insulin resistance (HOMA-IR \> 2.6). * At least one cardiometabolic risk factor: abdominal obesity (waist circumference \> 90 cm in men or \> 80 cm in women); low HDL-cholesterol (\< 40 mg/dL in men or \< 50 mg/dL in women); elevated LDL-cholesterol (\> 70 / 100 / 130 mg/dL, according to estimated cardiovascular risk); or elevated blood pressure (≥ 130/85 mmHg). Exclusion Criteria: * Diabetes diagnosis. * Severe psychiatric illness. * Malabsorption disorders or previous bariatric surgery. * Pregnancy or lactation. * Previous clinical cardiovascular disease. * Regular use of medications that could influence study outcomes, including: lipid-lowering agents insulin sensitizers antihypertensive drugs anticoagulants antiretroviral therapy thyroid hormones oral corticosteroids immunosuppressants polyunsaturated fatty acid (PUFA) supplements. * Fasting serum triglycerides ≥ 500 mg/dL or LDL-cholesterol ≥ 190 mg/dL. * Body mass index (BMI) ≥ 35 kg/m². * Very high blood pressure. * Any additional condition that may limit adherence to the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Insulin resistance are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Insulin Resistance metabolic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Insulin resistance Metabolic disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centro de Investigaciones Clínicas UC (CICUC) - Pontificia Universidad Católica de Chile

    RECRUITING

    Santiago, Santiago Metropolitan, 8330024, Chile

More trials for these conditions

Other studies related to the condition(s) this trial covers.